MicroRNA‑642a‑5p inhibits colon cancer cell migration and invasion by targeting collagen type I α1

Wang,Xiaoguang; Song,Zhengwei; Hu,Biwen; Chen,Zhenwei; Chen,Fei; Cao,Chenxi

doi:10.3892/or.2020.7905

MicroRNA‑642a‑5p inhibits colon cancer cell migration and invasion by targeting collagen type I α1

Authors:
- Xiaoguang Wang
- Zhengwei Song
- Biwen Hu
- Zhenwei Chen
- Fei Chen
- Chenxi Cao
View Affiliations

Affiliations: Department of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China
Published online on: December 18, 2020 https://doi.org/10.3892/or.2020.7905
Pages: 933-944
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the mechanism by which microRNA (miR)‑642a‑5p regulates the migration and invasion of colon cancer cells via collagen type I α1 (COL1A1). The characteristics of miR‑642a‑5p and COL1A1 were analysed through bioinformatics. Cancer and normal tissues were collected from patients with colon cancer. miR‑642a‑5p‑ and COL1A1‑overexpressing cell lines were constructed by transfection. A dual‑luciferase reporter assay was used to verify the targeting of COL1A1 by miR‑642a‑5p. Cell Counting Kit‑8, wound healing and Transwell assays were used to detect cell viability, migration and invasion, respectively. Protein and mRNA expression levels were examined by western blotting and reverse transcription‑quantitative PCR, respectively. The results revealed that miR‑642a‑5p expression was significantly upregulated and COL1A1 expression was downregulated in patients with colon cancer. Low levels of miR‑642a‑5p and high levels of COL1A1 were associated with a poor prognosis in patients with colon cancer. miR‑642a‑5p directly targeted the 3'‑untranslated region of COL1A1 and inhibited COL1A1 expression. Overexpression of miR‑642a‑5p inhibited cell viability, migration, invasion and epithelial mesenchymal transition. Overexpression of COL1A1 promoted cell viability, migration, invasion and EMT, and partially reversed the inhibitory effects of miR‑642a‑5p on colon cancer cells. In conclusion, miR‑642a‑5p inhibited colon cancer cell migration, invasion and EMT by regulating COL1A1.

View Figures

View References

1	Siegel R, Miller K and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Chen W: Cancer statistics: Updated cancer burden in China. Chin J Cancer Res. 27:12015. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, Yang Z, Li H, Zou X and He J: Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 30:1–12. 2018. View Article : Google Scholar : PubMed/NCBI
4	Weinberg BA, Marshall JL and Salem ME: The growing challenge of young adults with colorectal cancer. Oncology (Williston Park). 31:381–389. 2017.PubMed/NCBI
5	Chen TM, Huang YT and Wang GC: Outcome of colon cancer initially presenting as colon perforation and obstruction. World J Surg Oncol. 15:1642017. View Article : Google Scholar : PubMed/NCBI
6	Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics, 2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
7	You YN, Rustin RB and Sullivan JD: Oncotype DX(^®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence. Surg Oncol. 24:61–66. 2015. View Article : Google Scholar : PubMed/NCBI
8	Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al: International validation of the consensus immunoscore for the classification of colon cancer: A prognostic and accuracy study. Lancet. 391:2128–2139. 2018. View Article : Google Scholar : PubMed/NCBI
9	Simonson B and Das S: MicroRNA therapeutics: The next magic bullet? Mini Rev Med Chem. 15:467–474. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ritchie W: microRNA target prediction. Methods Mol Biol. 1513:193–200. 2017. View Article : Google Scholar : PubMed/NCBI
11	Xu J, Pan X and Hu Z: MiR-502 mediates esophageal cancer cell TE1 proliferation by promoting AKT phosphorylation. Biochem Biophys Res Commun. 501:119–123. 2018. View Article : Google Scholar : PubMed/NCBI
12	Xie F, Hosany S, Zhong S, Jiang Y, Zhang F, Lin L, Wang X, Gao S and Hu X: MicroRNA-193a inhibits breast cancer proliferation and metastasis by downregulating WT1. PLoS One. 12:e01855652017. View Article : Google Scholar : PubMed/NCBI
13	Shen H, Wang D, Li L, Yang S, Chen X, Zhou S, Zhong S, Zhao J and Tang J: MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene. 596:110–118. 2017. View Article : Google Scholar : PubMed/NCBI
14	Hussein NA, Kholy ZA, Anwar MM, Ahmad MA and Ahmad SM: Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer. J Cancer Res Clin Oncol. 143:83–93. 2017. View Article : Google Scholar : PubMed/NCBI
15	Paydas S, Acikalin A, Ergin M, Celik H, Yavuz B and Tanriverdi K: Micro-RNA (miRNA) profile in Hodgkin lymphoma: Association between clinical and pathological variables. Med Oncol. 33:342016. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Stuchbery R, Macintyre G, Cmero M, Harewood LM, Peters JS, Costello AJ, Hovens CM and Corcoran NM: Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression. Oncotarget. 7:31384–31392. 2016. View Article : Google Scholar : PubMed/NCBI
18	Liu L, Zhang C, Li X, Sun W, Qin S, Qin L and Wang X: miR-223 promotes colon cancer by directly targeting p120 catenin. Oncotarget. 8:63764–63779. 2017. View Article : Google Scholar : PubMed/NCBI
19	Zeng M, Zhu L, Li L and Kang C: miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1. Cell Mol Biol Lett. 22:122017. View Article : Google Scholar : PubMed/NCBI
20	Fu Q, Cheng J, Zhang J, Zhang Y, Chen X, Luo S and Xie J: miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer. Oncol Rep. 37:123–130. 2017. View Article : Google Scholar : PubMed/NCBI
21	Daniunaite K, Dubikaityte M, Gibas P, Bakavicius A, Rimantas Lazutka J, Ulys A, Jankevicius F and Jarmalaite S: Clinical significance of miRNA host gene promoter methylation in prostate cancer. Hum Mol Genet. 26:2451–2461. 2017. View Article : Google Scholar : PubMed/NCBI
22	Monterde-Cruz L, Ramirez-Salazar EG, Rico-Martinez G, Linares-González LM, Guzmán-González R, Delgado-Cedillo E, Estrada-Villaseñor E, Valdés-Flores M, Velázquez-Cruz R and Hidalgo-Bravo A: Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population. Hum Cell. 31:292–299. 2018. View Article : Google Scholar : PubMed/NCBI
23	Marchionni L, Hayashi M, Guida E, Ooki A, Munari E, Jabboure FJ, Dinalankara W, Raza A, Netto GJ, Hoque MO and Argani P: MicroRNA expression profiling of Xp11 renal cell carcinoma. Hum Pathol. 67:18–29. 2017. View Article : Google Scholar : PubMed/NCBI
24	Lin C and Zhang Y, Chen Y, Bai Y and Zhang Y: Long noncoding RNA LINC01234 promotes serine hydroxymethyltransferase 2 expression and proliferation by competitively binding miR-642a-5p in colon cancer. Cell Death Dis. 10:1372019. View Article : Google Scholar : PubMed/NCBI
25	Kirkland SC: Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells. Br J Cancer. 101:320–326. 2009. View Article : Google Scholar : PubMed/NCBI
26	Xia XY, Li WW, Li N, Wu QY, Cui YX and Li XJ: A novel mild variant of osteogenesis imperfecta type I caused by a Gly1088Glu mutation in COL1A1. Mol Med Rep. 9:2187–2190. 2014. View Article : Google Scholar : PubMed/NCBI
27	Liu S, Liao G and Li G: Regulatory effects of COL1A1 on apoptosis induced by radiation in cervical cancer cells. Cancer Cell Int. 17:732017. View Article : Google Scholar : PubMed/NCBI
28	Liu J, Shen JX, Wu HT, Li XL, Wen XF, Du CW and Zhang GJ: Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target. Discov Med. 25:211–223. 2018.PubMed/NCBI
29	Ma HP, Chang HL, Bamodu OA, Yadav VK, Huang TY, Wu ATH, Yeh CT, Tsai SH and Lee WH: Collagen 1A1 (COL1A1) is a reliable biomarker and putative therapeutic target for hepatocellular carcinogenesis and metastasis. Cancers (Basel). 11:7862019. View Article : Google Scholar
30	Yang W, Ma J, Zhou W, Li Z, Zhou X, Cao B, Zhang Y, Liu J, Yang Z, Zhang H, et al: Identification of hub genes and outcome in colon cancer based on bioinformatics analysis. Cancer Manag Res. 11:323–338. 2019. View Article : Google Scholar : PubMed/NCBI
31	Zhang Z, Wang Y, Zhang J, Zhong J and Yang R: COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway. Mol Med Rep. 17:5037–5042. 2018.PubMed/NCBI
32	Du F, Liu H, Lu Y, Zhao X and Fan D: Epithelial-to-mesenchymal transition: Liaison between cancer metastasis and drug resistance. Crit Rev Oncog. 22:275–282. 2017. View Article : Google Scholar : PubMed/NCBI
33	Brozovic A: The relationship between platinum drug resistance and epithelial-mesenchymal transition. Arch Toxicol. 91:605–619. 2017. View Article : Google Scholar : PubMed/NCBI
34	Mutlu M, Raza U, Saatci Ö, Eyüpoğlu E, Yurdusev E and Şahin Ö: miR-200c: A versatile watchdog in cancer progression, EMT, and drug resistance. J Mol Med (Berl). 94:629–644. 2016. View Article : Google Scholar : PubMed/NCBI
35	Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al: N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
36	Wang M, Ren D, Guo W, Huang S, Wang Z, Li Q, Du H, Song L and Peng X: N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells. Int J Oncol. 48:595–606. 2016. View Article : Google Scholar : PubMed/NCBI
37	Tian H, Lian R, Li Y, Liu C, Liang S, Li W, Tao T, Wu X, Ye Y, Yang X, et al: AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent vimentin degradation. Nat Commun. 11:51272020. View Article : Google Scholar : PubMed/NCBI
38	Cho SH, Park YS, Kim HJ, Kim CH, Lim SW, Huh JW, Lee JH and Kim HR: CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol. 41:211–218. 2012.PubMed/NCBI
39	Liu J, Eischeid AN and Chen XM: Col1A1 production and apoptotic resistance in TGF-β1-induced epithelial-to-mesenchymal transition-like phenotype of 603B cells. PLoS One. 7:e513712012. View Article : Google Scholar : PubMed/NCBI
40	Watabe M, Kochi M, Nishimaki H, Kano H, Tamegai H, Shimizu H, Matsuno Y, Kawai T, Masuda S, Sugitani M, et al: A case of advanced gastric cancer with bone marrow metastasis treated with low-dose combination chemotherapy containing S-1 and docetaxel. Gan To Kagaku Ryoho. 46:933–936. 2019.(In Japanese). PubMed/NCBI